Evidence map›Paper›PMID 40034702›Full record

ArticleFrontiers in immunology2025

Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts.

Bo Huang, Suilan Zheng, Kasireddy Sudarshan, Ramesh Mukkamala, Madduri Srinivasarao, Tushar Sardesai, Xiaofei Yang, Haiyan Chu, Philip S Low

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Small-molecule control of CAR T cells.Nature reviews. Chemistry · 2025
    Review
  9. Article
  10. Review
  11. Cell-Based Therapies for Solid Tumors: Challenges and Advances.International journal of molecular sciences · 2025
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bo HuangDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Suilan ZhengDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Kasireddy SudarshanDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Ramesh MukkamalaDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Madduri SrinivasaraoDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Tushar SardesaiDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Xiaofei YangDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Haiyan ChuDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.
Philip S LowDepartment of Chemistry and Institute for Drug Discovery, Purdue University, West Lafayette, IN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CAR T cells therapies have demonstrated success in treating hematologic malignancies, but have proven less effective in eradicating solid tumors. While suppressive immune cells may contribute to reduced CAR T cell efficacies in malignant masses, cancer-associated fibroblasts (CAFs) are also believed to facilitate tumor survival by secreting growth factors, immunosuppressive cytokines, and extracellular matrix components that inhibit drug and immune cell filtration and facilitate metastasis. In an effort to eliminate both CAFs and cancer cells simultaneously, we have employed a universal CAR T cell that can attack both cell types when supplemented with appropriate bispecific adapters. We show here that tumor regression is indeed enhanced when CAR T cells are directed to concurrently kill both cancer cells and CAFs. We further demonstrate that simultaneous targeting of both cell types enhances CAR T cell proliferation, activation, tumor infiltration, and tumor distribution relative to targeting only a single cell type. Because all of these benefits are achieved in both cold and hot tumors without significant toxicity, we conclude that use of a universal CAR T cell in combination with multiple bispecific adapters can provide a safe, potent, cost-effective, and scalable alternative to the treatment of solid tumors with conventional CAR T cells.

Indexed as

Cancer-Associated FibroblastsImmunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorHumansMiceXenograft Model Antitumor AssaysReceptors, Chimeric Antigencancer-associated fibroblasts (CAFs)fibroblast activation protein (FAP)solid tumorstumor microenvironmentuniversal CAR T cells

Identifiers

PMID40034702
PMCPMC11873807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.